Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

G Andersen, N H Jensen, Lona Louring Christrup, S H Hansen, P Sjøgren

14 Citations (Scopus)

Abstract

Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.
Original languageEnglish
JournalPalliative Medicine
Volume16
Issue number2
Pages (from-to)107-14
Number of pages8
ISSN0269-2163
Publication statusPublished - Mar 2002
Externally publishedYes

Keywords

  • Adult
  • Aged
  • Analgesics, Opioid
  • Delayed-Action Preparations
  • Female
  • Humans
  • Male
  • Middle Aged
  • Morphine
  • Morphine Derivatives
  • Neoplasms
  • Pain

Fingerprint

Dive into the research topics of 'Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine'. Together they form a unique fingerprint.

Cite this